Leerink Partnrs Has Negative Outlook of BBIO FY2028 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Stock analysts at Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for BridgeBio Pharma in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn $4.31 per share for the year, down from their prior forecast of $4.38. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($2.59) per share.

A number of other equities analysts have also recently issued reports on the stock. Evercore ISI dropped their price target on shares of BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $70.00 price objective on shares of BridgeBio Pharma in a research report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $43.00 price target on shares of BridgeBio Pharma in a research note on Friday, October 25th. Piper Sandler started coverage on BridgeBio Pharma in a report on Wednesday, September 4th. They issued an “overweight” rating and a $46.00 price objective for the company. Finally, Scotiabank began coverage on BridgeBio Pharma in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $44.00 target price on the stock. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $47.50.

BridgeBio Pharma Trading Up 2.5 %

BBIO traded up $0.63 during trading on Thursday, reaching $25.42. The stock had a trading volume of 192,863 shares, compared to its average volume of 1,834,889. The company has a market capitalization of $4.78 billion, a price-to-earnings ratio of -10.29 and a beta of 1.09. The stock’s 50 day moving average is $25.78 and its two-hundred day moving average is $26.44. BridgeBio Pharma has a one year low of $21.62 and a one year high of $44.32.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its position in shares of BridgeBio Pharma by 22.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 803,956 shares of the company’s stock worth $24,859,000 after purchasing an additional 145,594 shares during the period. Vanguard Group Inc. increased its position in shares of BridgeBio Pharma by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 13,222,126 shares of the company’s stock valued at $408,828,000 after acquiring an additional 421,832 shares during the period. Comerica Bank raised its stake in shares of BridgeBio Pharma by 3,013.5% in the first quarter. Comerica Bank now owns 38,514 shares of the company’s stock worth $1,191,000 after purchasing an additional 37,277 shares during the last quarter. Swiss National Bank lifted its stake in BridgeBio Pharma by 17.0% during the 1st quarter. Swiss National Bank now owns 206,000 shares of the company’s stock valued at $6,370,000 after acquiring an additional 29,900 shares during the period. Finally, Frazier Life Sciences Management L.P. boosted its holdings in BridgeBio Pharma by 6.4% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,632,604 shares of the company’s stock valued at $92,014,000 after purchasing an additional 217,000 shares during the last quarter. Institutional investors own 99.85% of the company’s stock.

Insider Buying and Selling at BridgeBio Pharma

In other news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the completion of the transaction, the insider now directly owns 25,260,971 shares in the company, valued at approximately $650,470,003.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Neil Kumar sold 27,389 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $24.69, for a total value of $676,234.41. Following the sale, the chief executive officer now directly owns 4,897,443 shares in the company, valued at approximately $120,917,867.67. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of BridgeBio Pharma stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the sale, the insider now owns 25,260,971 shares of the company’s stock, valued at $650,470,003.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,831,544 shares of company stock worth $150,128,821 in the last quarter. 24.66% of the stock is owned by corporate insiders.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.